Arrowhead Pharmaceuticals Files 10-Q for Q2 2025
Ticker: ARWR · Form: 10-Q · Filed: May 12, 2025 · CIK: 879407
Sentiment: neutral
Topics: 10-Q, financials, biopharmaceutical
Related Tickers: ARWR
TL;DR
ARWR 10-Q filed. Financials and ops update for period ending 3/31/25.
AI Summary
Arrowhead Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business operations. Key financial figures and operational highlights are detailed within the filing.
Why It Matters
This filing provides investors with the latest financial performance and operational status of Arrowhead Pharmaceuticals, crucial for understanding the company's trajectory in the competitive biopharmaceutical market.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Arrowhead faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Arrowhead Pharmaceuticals, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of the reporting period
- 20250512 (date) — Filing date
- Pasadena, CA (location) — Company headquarters
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 12, 2025.
What is Arrowhead Pharmaceuticals' Standard Industrial Classification code?
Arrowhead Pharmaceuticals' Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.
What is the company's fiscal year end?
The company's fiscal year ends on September 30.
What was the previous name of Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals was formerly known as Arrowhead Research Corp.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding ARROWHEAD PHARMACEUTICALS, INC. (ARWR).